No category in this field carries more expectation and less human evidence than the longevity compounds. That is not a dismissal — aging biology is legitimately among the most interesting research areas of the last twenty years. It is a description of where the science currently sits, which is much earlier than the conversation around it.
The class splits cleanly into three tiers.
Tier one: NAD⁺ precursors, where humans have actually been studied
Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors to NAD⁺, a coenzyme central to cellular metabolism whose levels decline with age across many tissues. This is the best-supported premise in the class, and it has produced real randomized human trials.
Martens and colleagues (Nature Communications, 2018) gave NR to healthy middle-aged and older adults in a placebo-controlled crossover design and reported that it reliably elevated blood NAD⁺ — the pharmacology works. They also reported a modest reduction in systolic blood pressure and arterial stiffness that the authors themselves framed as preliminary and hypothesis-generating.
That pattern repeats across the NAD⁺ trial literature: the biomarker moves, convincingly and reproducibly; the functional outcomes are small, mixed, or underpowered. Raising a molecule's concentration is a pharmacological result. Whether raising it changes how a person ages is the question the trials have not yet answered.
Tier two: mitochondrial peptides, real science at the preclinical stage
MOTS-c is a mitochondrial-derived peptide — encoded in mitochondrial DNA rather than nuclear DNA, which was itself a notable discovery. Lee and colleagues (Cell Metabolism, 2015) characterised it and reported effects on metabolic regulation and insulin sensitivity in mouse models.
That is genuine, well-published science in a serious journal. It is also mouse work. The literature on humans is limited to observational associations, and the compound has no completed clinical efficacy program. Everything said about MOTS-c and human aging is extrapolation from rodents and cell systems — interesting extrapolation, but the word matters.
Tier three: the telomere compounds, where the evidence gets thin
Epitalon is where this class's evidence problem is most acute. The compound comes out of a Russian research program (associated with Vladimir Khavinson) that has reported effects on telomerase activity and lifespan measures over several decades.
The difficulties are structural. Much of the work is published in Russian-language or low-circulation venues, sample sizes are small, blinding and randomization are often unclear or absent, and — the decisive point — independent replication outside the originating group is essentially absent. When a body of evidence has never been reproduced by anyone with no stake in it, that is a defining limitation, not a footnote.
Reading this class honestly
The tiers are the useful takeaway. NAD⁺ precursors have real randomized human trials showing a real biomarker effect and unproven functional benefit. Mitochondrial peptides have credible preclinical science and no human efficacy data. Telomere compounds have an unreplicated literature from a single program.
Those are three completely different evidentiary positions, routinely sold under one word: longevity. Knowing which tier a compound occupies is most of what separates an informed reader from a marketed one.
Research use only. No compound discussed here is FDA-approved for any indication, and nothing on this page is medical advice.
For research use only · Not for human or veterinary use · No compound discussed here is FDA-approved for any indication